Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
TRDA Stock Chart & Stats
$10.96
-$0.56(-3.25%)
At close: 4:00 PM EST
$10.96
-$0.56(-3.25%)
Day’s Range― - ―
52-Week Range$4.93 - $18.76
Previous CloseN/A
Volume35.15K
Average Volume (3M)247.06K
Market Cap
$428.82M
Enterprise Value-$33.96M
Total Cash (Recent Filing)$326.84M
Total Debt (Recent Filing)$52.40M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 18, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding38,219,230
10 Day Avg. Volume167,880
30 Day Avg. Volume247,064
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.50
Price to Sales (P/S)3.06
P/FCF Ratio-14.43
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-0.55
Enterprise Value/Gross Profit-1.47
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$16.50Price Target Upside50.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company ended 3Q25 with roughly $327M in cash, cash equivalents, and marketable securities, expected to be sufficient to fund operations into at least 3Q27.
Research And DevelopmentEntrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S.
Strategic PositioningEntrada continues to jockey for competitive positioning within the next-gen DMD dystrophin exon-skipping and DM1 space and has clear line of sight to 3 potential clinical catalysts in 2026.
Bears Say
Financial PerformanceEntrada reported a 3Q25 net loss of $1.06 vs. our estimate for a net loss of $1.11 per share; we currently project a full-year 2025 net loss of $3.67 per share, widening to a net loss of $4.21 per share in 2026.
Market PerceptionEntrada is considered an earlier-stage name, which could be a pushback despite the opportunities highlighted by Avidity's transaction.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $18.76 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $428.82M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Mar 18, 2026 which is in 88 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.94 by -$0.12.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -0.98.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,219,230 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.94. Following the earnings report the stock price went up 0.144%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (50.55% Upside)
$16.50 (50.55% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 122.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.18%
12-Months-Change
Fundamentals
Return on Equity
-27.11%
Trailing 12-Months
Asset Growth
-25.55%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Stock 12 Month Forecast
Average Price Target
$16.50
▲(50.55% Upside)
Technical Analysis
Genfit SA
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
Ventyx Biosciences
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
36.14% Insiders
9.03% Mutual Funds
42.52% Other Institutional Investors
4.25% Public Companies and
Individual Investors